Verona Pharma Stock Price, News & Analysis

Verona Pharma (Nasdaq: VRNA) reported its Q1 2021 financial results and provided an update on its Phase 3 ENHANCE clinical program for ensifentrine in COPD. The company continues to expect enrollment completion by H2 2021 and plans to announce top-line data in 2022. Financially, the company's cash position was $169.6 million, down from $188.0 million in Q4 2020. R&D expenses rose to $13.6 million from $7.6 million, and G&A expenses increased to $9.3 million from $6.9 million. The net loss for Q1 2021 was $21.3 million compared to $12.3 million in Q1 2020.

Verona Pharma (Nasdaq: VRNA) announced significant results from a Phase 2b trial of nebulized ensifentrine in patients with symptomatic COPD, published in the International Journal of Chronic Obstructive Pulmonary Disease. The 4-week study of 416 patients showed clinically and statistically significant dose-dependent improvements in lung function and quality of life when ensifentrine was added to tiotropium maintenance therapy. Ensifentrine, a dual inhibitor of PDE3 and PDE4, demonstrated a favorable safety profile, comparable to placebo.

Verona Pharma plc (Nasdaq: VRNA) announced findings from a pilot study on ensifentrine, a treatment for COVID-19. Conducted on 45 hospitalized patients, the study revealed ensifentrine was safe but did not demonstrate clinical efficacy when added to standard care. One patient death occurred in the ensifentrine group. Despite this, recovery rates were reportedly better than expected. Ensifentrine is currently in Phase 3 development for COPD, showing promise in improving lung function and reducing symptoms in earlier studies. The company is focused on respiratory diseases with unmet medical needs.

Verona Pharma (Nasdaq: VRNA) will release its financial results for Q1 2021 on April 29, 2021. A conference call is scheduled for 9:00 a.m. EDT featuring a corporate update. The company is focused on developing ensifentrine, a potential first-in-class therapy for respiratory diseases, currently in a Phase 3 program for COPD. Additional formulations are in Phase 2 trials. The company is also evaluating ensifentrine's use in COVID-19 and other respiratory conditions. Further details can be found on their website.

Verona Pharma plc (Nasdaq: VRNA) has appointed Ms. Lisa Deschamps as a Non-Executive Director effective March 1, 2021. Deschamps, previously Senior Vice President at Novartis Gene Therapies, brings extensive experience in strategic planning and commercialization in biopharmaceuticals. Her 25-year career at Novartis includes leading global franchises and achieving significant revenue targets. The board anticipates her expertise will support the progression of ensifentrine through Phase 3 trials. Verona Pharma focuses on innovative therapies for respiratory diseases, with ensifentrine aiming to combine bronchodilator and anti-inflammatory effects.

Verona Pharma plc (Nasdaq: VRNA), a clinical-stage biopharmaceutical firm specializing in respiratory diseases, has announced that CEO David Zaccardelli will provide a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be accessible on-demand starting 7:00 AM ET on March 9, 2021. It will be available for 90 days on the company’s Investors page. Verona Pharma is focused on developing ensifentrine, aimed at treating chronic obstructive pulmonary disease (COPD) with unique bronchodilator and anti-inflammatory properties.

Verona Pharma (VRNA) announced positive Phase 2 results for ensifentrine in COPD and ongoing enrollment in the Phase 3 ENHANCE program. The company secured a $30 million debt finance facility, enhancing financial flexibility. For Q4 2020, the net loss was $24.8 million, an increase from $9.5 million in Q4 2019. Cash and equivalents stood at $188 million at the end of 2020, bolstered by a $200 million private placement. The company expects to report top-line data from COVID-19 and ENHANCE studies in 2021 and 2022, respectively.

Verona Pharma (Nasdaq: VRNA) will report its fourth quarter and full year financial results for 2020 on February 25, 2021. A conference call for investors will take place at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these results and provide a corporate update. The company is known for developing therapies for respiratory diseases, notably ensifentrine, which is in Phase 3 trials for COPD treatment. The funds from a $200 million private placement in July 2020 are expected to support operations into 2023.

Verona Pharma announces the presentation of new analyses from a Phase 2b clinical trial of ensifentrine for chronic obstructive pulmonary disease (COPD) at the CHEST Annual Meeting 2020. The data indicate that adding nebulized ensifentrine to tiotropium provides significant improvements in quality of life and inspiratory capacity over four weeks. Furthermore, additional analyses highlight a rapid bronchodilator response with a pressurized metered-dose inhaler (pMDI) formulation, sustained for 12 hours. This data suggests ensifentrine’s dual mechanism of action may effectively manage COPD symptoms.